Intended Audience: Nephrologists, Cardiologists, Endocrinologists, Primary Care Physicians and their clinical teams (NPs, PAs, nurses, and pharmacists) caring for patients with T2D and CKD

Diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD) coexist in a complex, interrelated relationship. Diabetes is the leading cause of CKD, which if untreated, can progress to end-stage kidney disease, increase risk for cardiovascular events, and substantially impact patient quality of life, morbidity, and mortality. However, with new therapies for diabetic kidney disease emerging, there is an unprecedented opportunity to reduce the incidence of deadly cardiometabolic renal complications associated with diabetes.

Tune in to hear a panel of faculty experts with clinical expertise in diabetes, renal disease, and cardiovascular disease join forces to share their unique practice perspectives and:

• Review the bidirectional relationship between type 2 diabetes (T2D), CKD, and CVD and the associated risk of experiencing cardio-renal complications
• Examine best practices for screening and diagnosis of CKD in patients with T2D
• Interpret the latest evidence on emerging therapies for CKD in patients with T2D to create individualized management plans
• Identify strategies for effective care coordination and comprehensive management of T2D patients with cardiometabolic renal diseases through case-based discussions

• Describe the role of the mineralocorticoid receptor in the progression of CKD and the residual risk for cardio-renal events in patients with concomitant T2D and CKD
• Apply guideline-recommended screening and diagnostic evaluation for CKD in patients with T2D
• Differentiate treatments for CKD in patients with T2D based on their MOA and the latest clinical data on efficacy and safety
• Assess patient-specific risk and comorbidities to guide personalized treatment selection and management approaches
• Employ best practices for therapeutic monitoring and effective interprofessional care coordination in patients with cardiometabolic renal diseases

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• George Bakris, MD (Speaker)
  
  Advisory Board or Panel – Alnylam, AstraZeneca, Janssen, KBP Biosciences, Novo Nordisk
  Consultant – Alnylam, AstraZeneca, Janssen, KBP Biosciences, Novo Nordisk
  The relationships reported above are related to the following therapeutic area: Nephrology
• Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC (Speaker)
  
  Consultant – Amarin, Amgen, Bayer, Boehringer Ingelheim, Edwards Lifescience, Esperion, Medtronic, Novartis, Novo Nordisk, Pfizer
  Grants / Research Support – Merck
  The relationships reported above are related to the following therapeutic area: Cardiovascular/Cardio-metabolic disorders
• Sylvia Rosas, MD, MSCE (Speaker)
  
  Advisory Board or Panel – AstraZeneca, Bayer
  Grants / Research Support – AstraZeneca, Bayer
  The relationships reported above are related to the following therapeutic area: Nephrology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Stephanie Joyce, PA, MSPAS, MS, RD CNSC (Reviewer)
• Kevin O. Hwang, MD, MPH (Planner)
• Lisa Wakefield, MSN, APRN, FNP-BC (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.